Search results
Showing 7531 to 7545 of 8314 results
Pembrolizumab for previously treated oesophageal or gastro-oesophageal junction cancer [ID1357]
Discontinued Reference number: GID-TA10322
Listeria monocytogenes vaccine for previously treated malignant pleural mesothelioma ID1353
Discontinued Reference number: GID-TA10320
Discontinued Reference number: GID-TA10271
Guadecitabine for untreated acute myeloid leukaemia [ID1411]
Discontinued Reference number: GID-TA10325
PredictSURE IBD and IBDX to guide treatment of Crohn's disease (DG45)
We have moved Diagnostics guidance 45 to become HealthTech guidance 610. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
EarlyCDT Lung for assessing risk of lung cancer in solid lung nodules (DG46)
We have moved Diagnostics guidance 46 to become HealthTech guidance 611. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
We have moved Diagnostics guidance 47 to become HealthTech guidance 619. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care (DG48)
We have moved Diagnostics guidance 48 to become HealthTech guidance 682. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
PLGF-based testing to help diagnose suspected preterm pre-eclampsia (DG49)
We have moved Diagnostics guidance 49 to become HealthTech guidance 630. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
We have moved Diagnostics guidance 5 to become HealthTech guidance 291. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
MRI-based technologies for assessing non-alcoholic fatty liver disease (DG50)
We have moved Diagnostics guidance 50 to become HealthTech guidance 655. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
We have moved Diagnostics guidance 51 to become HealthTech guidance 657. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
We have moved Diagnostics guidance 52 to become HealthTech guidance 677. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
MRI fusion biopsy systems for diagnosing prostate cancer (DG53)
We have moved Diagnostics guidance 53 to become HealthTech guidance 678. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
We have moved Diagnostics guidance 54 to become HealthTech guidance 680. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.